Is Viridian Therapeutics, Inc. (VRDN) a Buy, Sell, or Hold?
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$19.08 USD
$0.09 (0.47%)
- Volume
- 1.14M
- Average Volume
- 2.55M
- Market Capitalization
- $1.72B
- P/E Ratio
- -5.48
- Dividend Yield
- 0.00%
- Price Target
- $38.50
- Year High
- $34.29
- Year Low
- $13.18
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Stephen F. Mahoney |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VRDN |
| CUSIP | 92790C104 |
| CIK | 0001590750 |
| Web | https://www.viridiantherapeutics.com |
| Phone | 617 272 4600 |
| Currency | USD |
| Employees | 252 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.08 |
| Payout Ratio | 0.00 |
| Current Ratio | 15.15 |
| Quick Ratio | 15.15 |
| Cash Ratio | 3.40 |
Sales & Book Value
| Annual Sales | $70.85M |
| Price / Sales | 24.21 |
| Cash Flow | -2.97 |
| Price / Cash Flow | -5.65 |
| Price / Book | 3.07 |
Price Target and Rating
| Average Stock Price Forecast | $38.50 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $26.00 |
| Forecast Upside/Downside | -50.44% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.32 |
| Trailing P/E Ratio | -5.48 |
| PEG Ratio | -1.25 |
| P/E Growth | -1.25 |
| Net Income | $-342.6M |
| Net Margin | -508.46% |
| Pretax Margin | -508.46% |
| Return on Equity | -60.70% |
| Return on Assets | -45.70% |
Financials Score
| AltmanZ Score | 3.88 |
| Piotroski Score | 2.00 |
| Working Capital | 732.94M |
| Total Assets | 789.02M |
| Ebit | -349.45M |
| Market Cap | 1.71B |
| Total Liabilities | 153.01M |
Poll Results
About Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021. ...
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
2026-07-01 11:45:49
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
2026-06-30 08:30:00
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
2026-06-29 14:12:09
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
2026-06-29 09:24:47
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
2026-06-26 18:00:00
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
2026-06-25 01:23:18
Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.
2026-06-10 00:02:19
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
2026-06-09 09:00:00
OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Labrador, with the first drill now turning on the initial hole of the Company's fully funded 2026 exploration program. The 2026 program is expected to consist of 50 diamond drill holes designed to systematically infill between widely spaced drill holes completed along the five-kilometre-long Main Zone conductive corridor, where mineralization has been intersected in holes spaced up to one kilometre apart.
Frequently Asked Questions
-
What is the current Viridian Therapeutics, Inc. (VRDN) stock price?
-
Viridian Therapeutics, Inc.(NASDAQ:VRDN) stock price is $19.08 in the last trading session. During the trading session, VRDN stock reached the peak price of $34.29 while $13.18 was the lowest point it dropped to. The percentage change in VRDN stock occurred in the recent session was 0.47% while the dollar amount for the price change in VRDN stock was $0.09.
-
VRDN's industry and sector of operation?
-
The NASDAQ listed VRDN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VRDN?
-
Jennifer Tousignant | Chief Legal Officer & Corporate Secretary
Melissa Manno | Chief Human Resources Officer
Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board
Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member
Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board -
How many employees does VRDN have?
-
Number of VRDN employees currently stands at 252. VRDN operates from 221 Crescent Street, Waltham, MA 02453, US.
-
Link for VRDN official website?
-
Official Website of VRDN is: https://www.viridiantherapeutics.com
-
How do I contact VRDN?
-
VRDN could be contacted at phone #617 272 4600 and can also be accessed through its website. VRDN operates from 221 Crescent Street, Waltham, MA 02453, US.
-
How many shares of VRDN are traded daily?
-
The average number of VRDN shares traded daily for last 3 months was 2.55M.
-
What is the market cap of VRDN currently?
-
The market value of VRDN currently stands at $1.72B with its latest stock price at $19.08